CorMedix Inc. to Present at Dawson James Securities Growth Stock Conference
BEDMINSTER, NJ–September 24, 2015–CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious diseases, today announced that Randy Milby, chief executive officer, will present an overview of the company at the Dawson James Securities Growth Stock Conference at the Wyndham Grand Hotel in Jupiter, FL on October 15, 2015 at 10:00 am EDT.
A live webcast and archived recording of the presentation will be available on the CorMedix website at www.CorMedix.com.
About CorMedix Inc.
CorMedix Inc. is a commercial-stage biopharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiorenal and infectious diseases. CorMedix’s first commercial product in Europe is Neutrolin(R), a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications. Plans are in progress to expand commercial distribution into the United States, Asia, and the Middle East upon appropriate regulatory approval. For more information visit www.cormedix.com.
Sam Brown Inc.